decernotinib

 
National Institutes of Health

Topic mentions per year

Topic mentions per year

2014-2018
024620142018

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
The past three decades have witnessed remarkable advances in our ability to target specific elements of the immune and… (More)
  • figure 1
  • figure 2
  • figure 3
  • figure 4
Is this relevant?
2016
2016
OBJECTIVE To assess the efficacy and safety of decernotinib (VX-509), an oral selective inhibitor of JAK-3, in patients with… (More)
Is this relevant?
2016
2016
(R)-2-((2-(1H-pyrrolo[2,3-b]pyridin-3-yl)pyrimidin-4-yl)amino)-2-methyl-N-(2,2,2-trifluoroethyl)butanamide (VX-509, decernotinib… (More)
Is this relevant?
2016
2016
OBJECTIVE To assess early effects on joint structures of VX-509 in combination with stable disease-modifying antirheumatic drug… (More)
Is this relevant?
2016
Review
2016
Review
2016
INTRODUCTION Treatment of rheumatoid arthritis (RA) has improved considerably following the advent of biologic disease-modifying… (More)
Is this relevant?
2015
2015
OBJECTIVE To assess the efficacy and safety of oral decernotinib (VX-509; Vertex Pharmaceuticals) monotherapy in a 12-week… (More)
Is this relevant?
2015
2015
While several therapeutic options exist, the need for more effective, safe, and convenient treatment for a variety of autoimmune… (More)
  • figure 1
  • figure 2
  • figure 3
  • table 2
  • figure 4
Is this relevant?
2015
2015
Cytokines, growth factors, and other chemical messengers rely on a class of intracellular nonreceptor tyrosine kinases known as… (More)
  • figure 1
  • table 1
  • table 2
  • table 3
  • table 4
Is this relevant?
Review
2014
Review
2014
INTRODUCTION The JAK kinases are a family of four tyrosine receptor kinases that play a pivotal role in cytokine receptor… (More)
Is this relevant?